Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.39 |
| ▸ | AURKA | O14965 | 5/20 | 0.33 |
| ▸ | ERN1 | O75460 | 2/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931389 | 0.90 | BRAF (0.46) | BRAFERN1 | |
| SCHEMBL9930833 | 0.81 | BRAF (0.52) | BRAFERN1 | |
| SCHEMBL10251286 | 0.81 | BRAF (0.57) | BRAF | |
| SCHEMBL9930889 | 0.79 | KDR (0.35) | BRAFAURKAAURKBRPS6KB1KDR | |
| SCHEMBL9930332 | 0.79 | BRAF (0.53) | BRAFERN1 | |
| SCHEMBL9930555 | 0.79 | BRAF (0.52) | BRAFERN1 | |
| SCHEMBL9930340 | 0.79 | BRAF (0.52) | BRAFERN1 | |
| SCHEMBL9930122 | 0.78 | BRAF (0.51) | BRAFERN1 | |
| SCHEMBL9930497 | 0.77 | BRAF (0.35) | BRAFAURKAAURKBRPS6KB1 | |
| SCHEMBL9930675 | 0.74 | BRAF (0.53) | BRAFERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885AURKA 1013/4885ERN1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.